• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对既往感染过 COVID-19 或 MIS-C 的儿科患者,针对 SARS-CoV-2 奥密克戎变异株的交叉反应性免疫较低。

Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.

机构信息

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, 20993, USA.

Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, 02115, USA.

出版信息

Nat Commun. 2022 May 27;13(1):2979. doi: 10.1038/s41467-022-30649-1.

DOI:10.1038/s41467-022-30649-1
PMID:35624101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9142524/
Abstract

Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5-11, 12-21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

摘要

儿童和青少年感染 SARS-CoV-2 后的中和抗体对奥密克戎的中和能力尚未得到充分研究。因此,我们通过年龄分层分析(<5 岁、5-11 岁、12-21 岁),评估了 177 名因严重急性 COVID-19、急性 MIS-C 住院的儿科患者以及 2020 年和 2021 年初轻度 COVID-19 门诊康复患者中针对 SARS-CoV-2 Alpha、Beta、Gamma、Delta 和奥密克戎变异株的病毒中和能力。在所有患者中,不到 10%的患者对奥密克戎显示出中和抗体滴度。与>5 岁的患者相比,因严重急性 COVID-19 住院的<5 岁儿童的 SARS-CoV-2 变异体中和抗体水平较低。如预期的那样,COVID-19 康复的儿科患者和 MIS-C 队列比急性 COVID-19 住院患者显示出更高的中和抗体滴度。总的来说,儿童和青少年对所有变异株的交叉中和能力都有一定程度的丧失,对奥密克戎的丧失最为明显。与 SARS-CoV-2 感染不同,接种两剂疫苗的儿童对 Alpha、Beta、Gamma、Delta 和奥密克戎的滴度更高。这些发现可能会影响新兴 SARS-CoV-2 变异株的传播、再感染和临床疾病结局,并支持儿童接种疫苗的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/907d0099d9d3/41467_2022_30649_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/28a65d09ed76/41467_2022_30649_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/252f18d4b09c/41467_2022_30649_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/cafaf3377a5a/41467_2022_30649_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/907d0099d9d3/41467_2022_30649_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/28a65d09ed76/41467_2022_30649_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/252f18d4b09c/41467_2022_30649_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/cafaf3377a5a/41467_2022_30649_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/9142524/907d0099d9d3/41467_2022_30649_Fig4_HTML.jpg

相似文献

1
Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.针对既往感染过 COVID-19 或 MIS-C 的儿科患者,针对 SARS-CoV-2 奥密克戎变异株的交叉反应性免疫较低。
Nat Commun. 2022 May 27;13(1):2979. doi: 10.1038/s41467-022-30649-1.
2
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.恢复期和接种疫苗血清对 SARS-CoV-2 原始株、Beta、Delta 和奥密克戎变异株临床分离株的免疫原性。
Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14.
3
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.儿童感染 SARS-CoV-2 或接种疫苗后对奥密克戎 BQ.1、BQ.1.1 和 XBB.1 变异株的中和作用。
Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y.
4
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.初次感染 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 株后中和抗体的不同反应特征
Front Immunol. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318. eCollection 2022.
5
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
6
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.对 SARS-CoV-2 恢复期患者队列的分析表明,β和奥密克戎变异株通过共同策略逃避了疫苗诱导的针对 RBD 的抗体。
EBioMedicine. 2022 Jun;80:104025. doi: 10.1016/j.ebiom.2022.104025. Epub 2022 May 6.
7
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低,但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
8
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
9
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.感染和接种后对 SARS-CoV-2 的异源中和活性。
Front Immunol. 2022 May 30;13:888794. doi: 10.3389/fimmu.2022.888794. eCollection 2022.
10
Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.新型冠状病毒肺炎进展:康复期血清中和抗体的持久性、有效性及免疫逃逸
Pathogens. 2022 Dec 13;11(12):1531. doi: 10.3390/pathogens11121531.

引用本文的文献

1
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.既往感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)会影响对奥密克戎BA.4/BA.5 mRNA加强针的适应性免疫反应。
J Allergy Clin Immunol. 2025 Jun;155(6):2038-2051. doi: 10.1016/j.jaci.2025.02.026. Epub 2025 Mar 3.
2
Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era.奥密克戎时代多重新冠病毒感染的下一代测序
Sci Rep. 2025 Jan 27;15(1):3372. doi: 10.1038/s41598-024-84952-6.
3
The Incidence and Clinical Characteristics of COVID-19 in Children With IBD During the Omicron Wave: A Single-Center Experience in China.

本文引用的文献

1
COVID reinfections surge during Omicron onslaught.在奥密克戎毒株肆虐期间,新冠病毒再次感染病例激增。
Nature. 2022 Feb 16. doi: 10.1038/d41586-022-00438-3.
2
SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变异株和感兴趣变异株的受体结合域突变与病毒传染性
Front Immunol. 2022 Jan 27;13:825256. doi: 10.3389/fimmu.2022.825256. eCollection 2022.
3
Rapid increase in Omicron infections in England during December 2021: REACT-1 study.2021 年 12 月英国奥密克戎感染迅速增加:REACT-1 研究。
奥密克戎毒株流行期间炎症性肠病患儿新冠病毒感染病的发病率及临床特征:一项中国单中心研究
Gastroenterol Res Pract. 2025 Jan 16;2025:1868214. doi: 10.1155/grp/1868214. eCollection 2025.
4
Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection.SARS-CoV-2奥密克戎感染后接种疫苗和未接种疫苗儿童的体液免疫和细胞免疫反应。
Clin Transl Immunology. 2024 Oct 3;13(10):e70008. doi: 10.1002/cti2.70008. eCollection 2024.
5
Evolution of the Antigenic Landscape in Children and Young Adults with COVID-19 and MIS-C.新冠病毒感染及儿童多系统炎症综合征患儿和青年成人抗原格局的演变
Vaccines (Basel). 2024 Jun 7;12(6):638. doi: 10.3390/vaccines12060638.
6
Timing of general anesthesia for pediatric patients recovering from COVID-19: a prospective cohort study.COVID-19 恢复期儿科患者全身麻醉时机:一项前瞻性队列研究。
BMC Anesthesiol. 2024 Jan 2;24(1):11. doi: 10.1186/s12871-023-02390-9.
7
Characteristics and Clinical Outcomes of Vaccine-Eligible US Children Under-5 Years Hospitalized for Acute COVID-19 in a National Network.符合条件的疫苗接种的美国 5 岁以下儿童在国家网络中因急性 COVID-19 住院的特征和临床结局。
Pediatr Infect Dis J. 2024 Mar 1;43(3):242-249. doi: 10.1097/INF.0000000000004225. Epub 2023 Dec 25.
8
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.儿童感染 SARS-CoV-2 或接种疫苗后对奥密克戎 BQ.1、BQ.1.1 和 XBB.1 变异株的中和作用。
Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y.
9
Susceptibility of bovine to SARS-CoV-2 variants of concern: insights from ACE2, AXL, and NRP1 receptors.牛对 SARS-CoV-2 关切变异株的易感性:来自 ACE2、AXL 和 NRP1 受体的见解。
Virol J. 2023 Nov 27;20(1):276. doi: 10.1186/s12985-023-02222-9.
10
Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth.出生后对 SARS-CoV-2 的黏膜和全身免疫的多组学分析。
Cell. 2023 Oct 12;186(21):4632-4651.e23. doi: 10.1016/j.cell.2023.08.044. Epub 2023 Sep 29.
Science. 2022 Mar 25;375(6587):1406-1411. doi: 10.1126/science.abn8347. Epub 2022 Feb 8.
4
Role of Omicron variant of SARS-CoV-2 in children in Germany.新冠病毒奥密克戎变异株在德国儿童中的作用。
World J Pediatr. 2022 Apr;18(4):283-284. doi: 10.1007/s12519-021-00511-3. Epub 2022 Feb 1.
5
Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.奥密克戎变异株对儿童自然感染 SARS-CoV-2 或接种 COVID-19 疫苗诱导产生的中和抗体的敏感性。
Emerg Microbes Infect. 2022 Dec;11(1):543-547. doi: 10.1080/22221751.2022.2035195.
6
Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children.新冠疫情:奥密克戎变种与幼儿住院人数急剧上升有关。
BMJ. 2022 Jan 14;376:o110. doi: 10.1136/bmj.o110.
7
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.辉瑞-生物科技的 BNT162b2 (Pfizer-BioNTech) mRNA 疫苗在 12-18 岁人群中预防儿童多系统炎症综合征的有效性-美国,2021 年 7 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):52-58. doi: 10.15585/mmwr.mm7102e1.
8
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
9
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.奥密克戎变异株对 SARS-CoV-2 表现出明显的抗体逃逸。
Nature. 2022 Feb;602(7898):676-681. doi: 10.1038/s41586-021-04388-0. Epub 2021 Dec 23.
10
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.